MET receptor tyrosine kinase as a therapeutic anticancer target

Christine M. Stellrecht; Varsha Gandhi

doi:10.1016/j.canlet.2008.10.045

MET receptor tyrosine kinase as a therapeutic anticancer target

Christine M. Stellrecht, Varsha Gandhi

Experimental Therapeutics

Research output: Contribution to journal › Review article › peer-review

53 Scopus citations

Abstract

Tyrosine kinases are frequently deregulated in cancer either by constitutive activation, mutation, or over-expression. Though they are often associated with an aggressive phenotype they are also proving to be a druggable target. Activation of the MET receptor tyrosine kinase promotes cell proliferation, scattering, invasion, survival, and angiogenesis. Deregulation of MET promotes tumor formation, growth, progression, metastasis, and therapeutic resistance. Because MET is a player in so many aspects of cancer development and progression, it is a strong candidate for targeted therapy. Numerous agents have been developed that are able to target MET expression and/or function and are the focus of this review.

Original language	English (US)
Pages (from-to)	1-14
Number of pages	14
Journal	Cancer Letters
Volume	280
Issue number	1
DOIs	https://doi.org/10.1016/j.canlet.2008.10.045
State	Published - Jul 18 2009

Keywords

Hepatocyte growth factor
Met
Receptor tyrosine kinase
Targeted therapy

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.canlet.2008.10.045

Cite this

@article{74d4a3aff1414e99a66e51df62aa4aae,

title = "MET receptor tyrosine kinase as a therapeutic anticancer target",

abstract = "Tyrosine kinases are frequently deregulated in cancer either by constitutive activation, mutation, or over-expression. Though they are often associated with an aggressive phenotype they are also proving to be a druggable target. Activation of the MET receptor tyrosine kinase promotes cell proliferation, scattering, invasion, survival, and angiogenesis. Deregulation of MET promotes tumor formation, growth, progression, metastasis, and therapeutic resistance. Because MET is a player in so many aspects of cancer development and progression, it is a strong candidate for targeted therapy. Numerous agents have been developed that are able to target MET expression and/or function and are the focus of this review.",

keywords = "Hepatocyte growth factor, Met, Receptor tyrosine kinase, Targeted therapy",

author = "Stellrecht, {Christine M.} and Varsha Gandhi",

note = "Funding Information: The preparation of this manuscript is in part supported by grant CA85915 from the NCI, Department of Health and Human Services and by a grant from the Center for Targeted Therapy of the University of Texas M.D. Anderson Cancer Center.",

year = "2009",

month = jul,

day = "18",

doi = "10.1016/j.canlet.2008.10.045",

language = "English (US)",

volume = "280",

pages = "1--14",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - MET receptor tyrosine kinase as a therapeutic anticancer target

AU - Stellrecht, Christine M.

AU - Gandhi, Varsha

N1 - Funding Information: The preparation of this manuscript is in part supported by grant CA85915 from the NCI, Department of Health and Human Services and by a grant from the Center for Targeted Therapy of the University of Texas M.D. Anderson Cancer Center.

PY - 2009/7/18

Y1 - 2009/7/18

N2 - Tyrosine kinases are frequently deregulated in cancer either by constitutive activation, mutation, or over-expression. Though they are often associated with an aggressive phenotype they are also proving to be a druggable target. Activation of the MET receptor tyrosine kinase promotes cell proliferation, scattering, invasion, survival, and angiogenesis. Deregulation of MET promotes tumor formation, growth, progression, metastasis, and therapeutic resistance. Because MET is a player in so many aspects of cancer development and progression, it is a strong candidate for targeted therapy. Numerous agents have been developed that are able to target MET expression and/or function and are the focus of this review.

AB - Tyrosine kinases are frequently deregulated in cancer either by constitutive activation, mutation, or over-expression. Though they are often associated with an aggressive phenotype they are also proving to be a druggable target. Activation of the MET receptor tyrosine kinase promotes cell proliferation, scattering, invasion, survival, and angiogenesis. Deregulation of MET promotes tumor formation, growth, progression, metastasis, and therapeutic resistance. Because MET is a player in so many aspects of cancer development and progression, it is a strong candidate for targeted therapy. Numerous agents have been developed that are able to target MET expression and/or function and are the focus of this review.

KW - Hepatocyte growth factor

KW - Met

KW - Receptor tyrosine kinase

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=67349189814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349189814&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2008.10.045

DO - 10.1016/j.canlet.2008.10.045

M3 - Review article

C2 - 19100682

AN - SCOPUS:67349189814

SN - 0304-3835

VL - 280

SP - 1

EP - 14

JO - Cancer Letters

JF - Cancer Letters

IS - 1

ER -

MET receptor tyrosine kinase as a therapeutic anticancer target

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this